Correction to: Combination Therapy with Pirfenidone plus Prednisolone Ameliorates Paraquat-Induced Pulmonary Fibrosis (Inflammation, (2018), 41, 1, (134-142), 10.1007/s10753-017-0671-9);Combination Therapy with Pirfenidone plus Prednisolone Ameliorates Paraquat-Induced Pulmonary Fibrosis

Inflammation

Volumn 41, Issue 1, 2018, Pages 134-142

  Rasooli, Rokhsana ^a   Pourgholamhosein, Fatemeh ^b   Kamali, Younes ^a   Nabipour, Fatemeh ^c   Mandegary, Ali ^d  

^a SHIRAZ UNIVERSITY   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

combination therapy; paraquat induced pulmonary fibrosis; pirfenidone; prednisolone

Indexed keywords

COLLAGEN; GELATINASE A; HYDROXYPROLINE; MESSENGER RNA; PARAQUAT; PIRFENIDONE; PREDNISOLONE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; ANTIINFLAMMATORY AGENT; AUTACOID; GLUCOCORTICOID; MMP2 PROTEIN, RAT; PYRIDONE DERIVATIVE; TGFB1 PROTEIN, RAT; TISSUE INHIBITOR OF METALLOPROTEINASE-1 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION DRUG THERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION REGULATION; LUNG FIBROSIS; LUNG PARENCHYMA; LUNG STRUCTURE; MALE; NONHUMAN; OXIDATIVE STRESS; PARAQUAT POISONING; PNEUMONIA; RAT; TREATMENT DURATION; ANIMAL; CELL PROTECTION; CHEMICALLY INDUCED; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; GENETICS; LUNG; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; HYDROXYPROLINE; INFLAMMATION MEDIATORS; LUNG; MALE; MATRIX METALLOPROTEINASE 2; OXIDATIVE STRESS; PARAQUAT; PREDNISOLONE; PULMONARY FIBROSIS; PYRIDONES; RATS, SPRAGUE-DAWLEY; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85029580356     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-017-0695-1     Document Type: Erratum

References (34)

1. Wuyts, W.A., K.M. Antoniou, K. Borensztajn, U. Costabel, V. Cottin, B. Crestani, J.C. Grutters, T.M. Maher, V. Poletti, and L. Richeldi. 2014. Combination therapy: the future of management for idiopathic pulmonary fibrosis? The Lancet Respiratory Medicine 2: 933–942.
2. Raghu, G., W.J. Depaso, K. Cain, S.P. Hammar, C.E. Wetzel, D.F. Dreis, J. Hutchinson, N.E. Pardee, and R.H. Winterbauer. 1991. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. American Review of Respiratory Disease 144: 291–296.
3. Kondoh, Y., H. Taniguchi, T. Yokoi, O. Nishiyama, T. Ohishi, T. Kato, K. Suzuki, and R. Suzuki. 2005. Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia. European Respiratory Journal 25: 528–533.
4. Khodayar, M.J., M. Kiani, A.A. Hemmati, A. Rezaie, M.R. Zerafatfard, M. Rashidi Nooshabadi, and M. Goudarzi. 2014. The preventive effect of atorvastatin on paraquat-induced pulmonary fibrosis in the rats. Adv Pharm Bull 4: 345–349.
5. Pourgholamhossein, F., F. Sharififar, R. Rasooli, L. Pourgholi, F. Nakhaeipour, H. Samare-Fekri, M. Iranpour, and A. Mandegary. 2016. Thymoquinone effectively alleviates lung fibrosis induced by paraquat herbicide through down-regulation of pro-fibrotic genes and inhibition of oxidative stress. Environmental Toxicology and Pharmacology 45: 340–345.
6. Ashcroft, T., J.M. Simpson, and V. Timbrell. 1988. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. Journal of Clinical Pathology 41: 467–470.
7. Azuma, A., T. Nukiwa, E. Tsuboi, M. Suga, S. Abe, K. Nakata, Y. Taguchi, S. Nagai, H. Itoh, and M. Ohi. 2005. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 171: 1040–1047.
8. Oku, H., T. Shimizu, T. Kawabata, M. Nagira, I. Hikita, A. Ueyama, S. Matsushima, M. Torii, and A. Arimura. 2008. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. European Journal of Pharmacology 590: 400–408.
9. Sur, S., J.S. Wild, B.K. Choudhury, N. Sur, R. Alam, and D.M. Klinman. 1999. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. Journal of Immunology 162: 6284–6293.
10. Samareh-Fekri, M., H.R. Poursalehi, A. Mandegary, F. Sharififar, R. Mahmoudi, A. Izadi, M.H. Nematolahi, N. Jamshidi, F. Pourgholamhossein, and M.R. Lashkarizadeh. 2015. The effect of methanol extract of fennel on bleomycin-induced pulmonary fibrosis in rats. Journal of Kerman University of Medical Sciences 22: 470–483.
11. Beyer, W.F., and I. Fridovich. 1987. Assaying for superoxide dismutase activity: some large consequences of minor changes in conditions. Analytical Biochemistry 161: 559–566.
12. Aebi, H. 1984. [13] Catalase in vitro. Methods in Enzymology 105: 121–126.
13. Reddy, G.K., and C.S. Enwemeka. 1996. A simplified method for the analysis of hydroxyproline in biological tissues. Clinical Biochemistry 29: 225–229.
14. Ghazi-Khansari, M., A. Mohammadi-Karakani, M. Sotoudeh, P. Mokhtary, E. Pour-Esmaeil, and S. Maghsoud. 2007. Antifibrotic effect of captopril and enalapril on paraquat-induced lung fibrosis in rats. Journal of Applied Toxicology 27: 342–349.
15. Tsai, W.-T. 2013. A review on environmental exposure and health risks of herbicide paraquat. Toxicological & Environmental Chemistry 95: 197–206.
16. Dong, J., X. Yu, D.W. Porter, L.A. Battelli, M.L. Kashon, and Q. Ma. 2016. Common and distinct mechanisms of induced pulmonary fibrosis by particulate and soluble chemical fibrogenic agents. Archives of Toxicology 90: 385–402.
17. Raghu, G., H.R. Collard, J.J. Egan, F.J. Martinez, J. Behr, K.K. Brown, T.V. Colby, J.-F. Cordier, K.R. Flaherty, and J.A. Lasky. 2011. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. American Journal of Respiratory and Critical Care Medicine 183: 788–824.
18. Rafii, R., M.M. Juarez, T.E. Albertson, and A.L. Chan. 2013. A review of current and novel therapies for idiopathic pulmonary fibrosis. Journal of Thoracic Disease 5: 48–73.
19. M-w, Liu, R. Liu, H.-y. Wu, Li Y-y, Su M-x, M.-n. Dong, W. Zhang, and C.-y. Qian. 2016. Radix puerariae extracts ameliorate paraquat-induced pulmonary fibrosis by attenuating follistatin-like 1 and nuclear factor erythroid 2p45-related factor-2 signalling pathways through downregulation of miRNA-21 expression. BMC Complementary and Alternative Medicine 16: 1.
20. Sayes, C.M., A.M. Gobin, K.D. Ausman, J. Mendez, J.L. West, and V.L. Colvin. 2005. Nano-C 60 cytotoxicity is due to lipid peroxidation. Biomaterials 26: 7587–7595.
21. Dou, T., M. Yan, X. Wang, W. Lu, L. Zhao, D. Lou, C. Wu, X. Chang, and Z. Zhou. 2016. Nrf2/ARE pathway involved in oxidative stress induced by paraquat in human neural progenitor cells. Oxidative Medicine and Cellular Longevity 2015.
22. Salazar-Montes, A., L. Ruiz-Corro, A. López-Reyes, E. Castrejón-Gómez, and J. Armendáriz-Borunda. 2008. Potent antioxidant role of pirfenidone in experimental cirrhosis. European Journal of Pharmacology 595: 69–77.
23. Toygar, M., I. Aydin, M. Agilli, F. Aydin, M. Oztosun, H. Gul, E. Macit, Y. Karslioglu, T. Topal, and B. Uysal. 2014. The relation between oxidative stress, inflammation, and neopterin in the paraquat-induced lung toxicity. Human & Experimental Toxicology. https://doi.org/10.1177/0960327114533808.
24. Lee, I.T., C.C. Lin, Y.C. Wu, and C.M. Yang. 2010. TNF-α induces matrix metalloproteinase-9 expression in A549 cells: Role of TNFR1/TRAF2/PKCα-dependent signaling pathways. Journal of Cellular Physiology 224: 454–464.
25. Leask, A., and D.J. Abraham. 2004. TGF-β signaling and the fibrotic response. The FASEB Journal 18: 816–827.
26. Mukherjee, S., M.R. Kolb, F. Duan, and L.J. Janssen. 2012. Transforming growth factor–β evokes Ca2+ waves and enhances gene expression in human pulmonary fibroblasts. American Journal of Respiratory Cell and Molecular Biology 46: 757–764.
27. Patel, A.S., L. Lin, A. Geyer, J.A. Haspel, C.H. An, J. Cao, I.O. Rosas, and D. Morse. 2012. Autophagy in idiopathic pulmonary fibrosis. PloS One 7: e41394.
28. Takeda, Y., K. Tsujino, T. Kijima, and A. Kumanogoh. 2014. Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis. Patient Preference and Adherence 8: 361–370.
29. Wynn, T.A., and T.R. Ramalingam. 2012. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nature Medicine 18: 1028–1040.
30. Dancer, R., A. Wood, and D. Thickett. 2011. Metalloproteinases in idiopathic pulmonary fibrosis. European Respiratory Journal 38: 1461–1467.
31. Visse, R., and H. Nagase. 2003. Matrix metalloproteinases and tissue inhibitors of metalloproteinases structure, function, and biochemistry. Circulation Research 92: 827–839.
32. Woessner, J.F. 1991. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. The FASEB Journal 5: 2145–2154.
33. Nagase, H., R. Visse, and G. Murphy. 2006. Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular Research 69: 562–573.
34. Ruiz, V., R.M. Ordóñez, J. Berumen, R. Ramirez, B. Uhal, C. Becerril, A. Pardo, and M. Selman. 2003. Unbalanced collagenases/TIMP-1 expression and epithelial apoptosis in experimental lung fibrosis. American Journal of Physiology-Lung Cellular and Molecular Physiology 285: L1026–L1036.